FDA Post-Election Landscape Debated By Former Agency Officials
This article was originally published in The Gray Sheet
Executive Summary
Medical device manufacturers should expect FDA to defer decisions with policy consequences until after the November Presidential election, according to Alston & Bird Partner Marc Scheineson